2 Major Reasons to Buy Moderna Stock Before July 31

Moderna (NASDAQ:MRNA) enters a captious six-day agelong with Q2 net owed July 31, and an FDA determination connected its seasonal flu vaccine expected August 5. Although the banal has already gained 83% successful 2026, 5 consecutive net beats and a imaginable 5th commercialized merchandise springiness investors 2 large catalysts to watch.

Moderna Has Beaten Earnings 5 Quarters successful a Row

Q1 2026 gross landed astatine $389M against $236.36M consensus, a 64.58% bushed connected 263.6% YoY growth. That extends a streak of five consecutive quarterly beats, with an average one-week post-earnings determination of 5.26%. Polymarket traders are pricing an 84% probability Moderna beats again, and the July 31 expiration put/call ratio sits astatine conscionable 0.12, 1 of the astir call-skewed stocks up of earnings.

An August 5 mRNA-1010 Approval Would Give Moderna Its Fifth Product

An August 5 support for mRNA-1010 (Moderna's 5th commercialized product, if cleared) rebuilds the respiratory franchise heading into the 2026 to 2027 flu season. Management reaffirmed up to 10% gross growth connected a $1.94B 2025 base and a year-end 2026 currency and investments presumption of $4.5-$5.0B.

Beyond that, Phase 3 adjuvant melanoma information for intismeran, which is being developed alongside Merck's KEYTRUDA and reduced the hazard of recurrence oregon decease by 49% versus KEYTRUDA alone, are owed aboriginal this year, on with norovirus and propionic acidemia readouts.

Act now: the expert who called NVIDIA successful 2010 conscionable named his apical 10 AI stocks — and Moderna didn't marque the cut. Grab the names FREE today.

The Bottom Line: Moderna Faces 2 Major Catalysts

Moderna continues to station ample GAAP losses, but its Q1 effect included an $878 cardinal litigation settlement that did not bespeak the underlying business. Management inactive expects to decorativeness 2026 with $4.5-$5 cardinal successful currency and investments, providing runway for respective upcoming objective readouts.

Friday's net report volition trial whether gross continues to recover, portion the August 5 FDA decision could adhd a 5th commercialized merchandise up of the adjacent flu season. Together, those events could find whether Moderna's 2026 rally has much country to run.

Act now: the expert who called NVIDIA successful 2010 conscionable named his apical 10 AI stocks — and Moderna didn't marque the cut. Grab the names FREE today.